Bolt Biotherapeutics, Inc. develops immunotherapies aimed at treating cancer by harnessing the innate immune system. The company utilizes its Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform to create product candidates that combine tumor-targeting antibodies with immune-stimulating payloads. Bolt's pipeline includes BDC-4182, which targets claudin 18.2 in various cancers, and it is engaged in clinical trials and partnerships to advance its therapeutic programs.
